How Does FGF21 Work? Mechanism of Action, Per the Research

Fibroblast growth factor 21 (FGF21) is an endocrine member of the fibroblast growth factor family. Unlike classical fibroblast growth factors that act locally on neighbouring cells, reviews of its pharmacology described FGF21 as a circulating hormone released mainly by the liver that acts on distant tissues through fibroblast growth factor receptors paired with the co-receptor beta-Klotho (PMID 33758421). That co-receptor requirement is the single most important point in any mechanistic description of FGF21, because it explains why a hormone with receptors on nearly every cell type only produces effects in a narrow set of tissues. A broader background on the molecule itself is covered in the FGF21 overview.

Receptor Targets: FGFR1c Plus Beta-Klotho

Reviews of FGF21 biology reported that FGF21 binds fibroblast growth factor receptors of the "c" splice variant class, principally FGFR1c, and that this binding requires beta-Klotho (encoded by KLB) as an obligate co-receptor to form a productive signalling complex (PMID 33758421). A separate review of the therapeutic landscape described the same receptor and co-receptor arrangement as the basis for engineering FGF21 analogues and FGFR1c/beta-Klotho agonist antibodies that mimic the native ligand (PMID 32764725).

Why the Co-Receptor Determines Tissue Selectivity

Because beta-Klotho expression is limited rather than universal, the tissues capable of responding to FGF21 are correspondingly limited. Review literature on FGF21 described white and brown adipose tissue, the liver and defined regions of the central nervous system as the principal beta-Klotho expressing targets, and framed this distribution as the reason FGF21 produces a coordinated metabolic response rather than a generalised growth factor response (PMID 33758421). A review focused on type 2 diabetes made the related point that this receptor selectivity has been treated as an attractive feature in drug design, since it narrows where a systemically delivered agonist can act (PMID 27031294).

After Binding: Signalling and Intracellular Trafficking

Once the FGF21, FGFR1c and beta-Klotho complex forms, reviews described receptor dimerisation and activation of the canonical fibroblast growth factor receptor tyrosine kinase cascade, including mitogen activated protein kinase signalling, as the proximal intracellular event that leads to changes in gene expression in responsive tissues (PMID 33758421). The therapeutic review placed the same cascade at the centre of attempts to engineer longer acting analogues with preserved receptor engagement (PMID 32764725).

Receptor engagement is only part of the picture. A 2019 eLife study used cryo-electron tomography combined with gold nanoparticle labelling to visualise FGF21 trafficking inside intact human cells, and the researchers reported that this approach resolved where labelled FGF21 was located within cells rather than relying on indirect markers (PMID 30688648). That work is cell-based imaging, not a clinical finding, and it describes how the ligand is handled after it meets the cell surface.

Where FGF21 Comes From: Stress Driven Expression

FGF21 is not secreted at a constant rate. Reviews characterised it as a stress and nutrient responsive hormone whose hepatic expression rises under conditions such as fasting, nutrient stress and specific dietary challenges, with transcriptional control involving stress responsive factors (PMID 33758421). A 2026 in vitro study in human HepG2 hepatocytes reported that the natural compound osthole increased FGF21 expression by mediating activation of the transcription factor ATF4, which is consistent with the integrated stress response acting as one upstream driver of FGF21 transcription (PMID 41596648). That result came from a cell line, not from animals or humans.

Other organs can also drive hepatic FGF21. A 2023 Science Advances study described an interleukin 6, STAT3, mineralocorticoid receptor and FGF21 axis mediating heart to liver cross-talk after myocardial infarction, placing hepatic FGF21 induction downstream of signals originating in injured heart tissue (PMID 37018396). Hepatic nutrient sensing pathways that operate alongside FGF21 biology have also been examined directly: a 2025 Journal of Hepatology study reported that protein phosphatase 6 regulated metabolic dysfunction associated steatohepatitis through the mTORC1 pathway (PMID 39947331).

Central Nervous System Actions in Animal Work

A substantial part of the proposed mechanism of FGF21 is neural rather than purely peripheral. A 2025 Cell Metabolism study reported that FGF21 reversed metabolic dysfunction associated steatohepatitis through coordinated actions on the central nervous system and the liver, indicating that the brain component was not incidental to the hepatic outcome in that preclinical model (PMID 40367940).

Circuit level work has gone further. A 2022 Cell Metabolism study reported that FGF21 suppressed alcohol consumption through an amygdalo-striatal circuit, identifying a defined brain pathway rather than a diffuse central effect (PMID 35108517). Review literature placed such central actions within the broader description of FGF21 as a hormone that influences energy balance and macronutrient preference through beta-Klotho expressing neurons (PMID 33758421). These are animal findings and have not been shown here to translate to human behaviour.

Peripheral Tissue Actions: Fat, Liver and Heart

Adipose Tissue

A 2018 Nature Communications study reported that FGF21 increased insulin sensitivity through specific expansion of subcutaneous fat, which positioned adipose remodelling as a mediator of the systemic metabolic effect rather than a side consequence of it (PMID 29348470). Reviews of FGF21 pharmacology similarly described adipose tissue as a primary site of action, with adiponectin and adipose derived signals discussed as candidate intermediates between the receptor complex and whole body glucose handling (PMID 33758421).

Liver

Hepatic effects have been described in both directions: the liver is the main source of circulating FGF21 and also a target tissue. The 2025 Cell Metabolism study reported that the hepatic response formed part of a coordinated central and peripheral programme in a steatohepatitis model (PMID 40367940), while the therapeutic review summarised lipid and liver fat related findings as a central reason FGF21 analogues entered clinical development for metabolic disease (PMID 32764725).

Heart and Mitochondria

A 2022 Circulation study reported that an FGF21 to Sirtuin 3 axis conferred protective effects of exercise against diabetic cardiomyopathy by governing mitochondrial integrity in a preclinical model (PMID 36134579). That work links FGF21 signalling to a downstream mitochondrial regulator rather than to glucose handling alone, and it remains animal and cell level evidence.

Established Mechanism Versus Proposed Mechanism

Signalling Trade-Offs and Unwanted Effects: What Studies Report

FGF21 signalling is not uniformly favourable in every context. A 2024 Cell Metabolism study reported that tumour-secreted FGF21 acted as an immune suppressor by rewiring cholesterol metabolism of CD8 positive T cells, which illustrates that the same pathway can be co-opted in disease settings (PMID 38309268). The therapeutic review discussed the gap between preclinical promise and clinical translation for FGF21 based agents, including the pharmacokinetic limitations of native FGF21 that motivated engineered analogues (PMID 32764725). A diabetes focused review likewise framed FGF21 as an emerging target under investigation rather than a settled therapy (PMID 27031294). The verified literature summarised on this page does not establish a safety profile for FGF21 or FGF21 analogues in healthy people.

Model Caveats: What the Evidence Base Is Made Of

Several of the mechanistic studies cited here were conducted in animals or in cultured cells, and the distinction matters when reading mechanism claims:

• The amygdalo-striatal circuit finding came from preclinical work on alcohol consumption (PMID 35108517).
• The ATF4 driven increase in FGF21 expression was observed in the HepG2 human hepatocyte cell line (PMID 41596648).
• The trafficking data came from imaging of intact human cells using cryo-electron tomography (PMID 30688648).
• The Sirtuin 3 and mitochondrial integrity axis was described in a diabetic cardiomyopathy model (PMID 36134579).
• The heart to liver interleukin 6, STAT3, mineralocorticoid receptor and FGF21 axis was described after myocardial infarction in a preclinical setting (PMID 37018396).

Receptor level pharmacology is the most consistently supported part of the mechanism across reviews (PMID 33758421), while circuit specific and tissue specific details are best read as mechanistic hypotheses supported by particular models (PMID 40367940).

Educational Disclaimer

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, medication or investigational compound. No dosing, administration or protocol information is provided here, and nothing on this page describes an approved use of FGF21 or FGF21 analogues outside of what the cited publications reported (PMID 32764725).

References

• Metabolic Messengers: FGF21 (Nature Metabolism, 2021)
• The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic (Nature Reviews Endocrinology, 2020)
• Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus (Medicinal Research Reviews, 2016)
• FGF21 reverses MASH through coordinated actions on the CNS and liver (Cell Metabolism, 2025)
• FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit (Cell Metabolism, 2022)
• Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8(+) T cells (Cell Metabolism, 2024)
• Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat (Nature Communications, 2018)
• FGF21-Sirtuin 3 Axis Confers the Protective Effects of Exercise Against Diabetic Cardiomyopathy by Governing Mitochondrial Integrity (Circulation, 2022)
• An IL-6/STAT3/MR/FGF21 axis mediates heart-liver cross-talk after myocardial infarction (Science Advances, 2023)
• Protein phosphatase 6 regulates metabolic dysfunction-associated steatohepatitis via the mTORC1 pathway (Journal of Hepatology, 2025)
• FGF21 trafficking in intact human cells revealed by cryo-electron tomography with gold nanoparticles (eLife, 2019)
• Osthole Activates FGF21 Expression by Mediating Activation of ATF4 in Human Hepatocyte HepG2 Cells (International Journal of Molecular Sciences, 2026)